NASDAQ · PFSA
Healthcare · Medical - Equipment & Services
$2.18
Down-$0.85 (-28.05%)
Updated Sep 27, 2026, 6:34 PM
SID Score
5.3/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 19 trading sessions · Daily adjusted prices
PFSA closed at $2.18 after 19 trading sessions, down 27.33% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 25, 2026 | $2.70 | $2.75 | $2.10 | $2.18 | 2.54M |
| Sep 24, 2026 | $3.51 | $4.18 | $2.39 | $3.03 | 79.27M |
| Sep 23, 2026 | $1.88 | $2.38 | $1.8622 | $2.05 | 1.86M |
| Sep 22, 2026 | $1.89 | $2.23 | $1.85 | $2.17 | 4.05M |
| Sep 21, 2026 | $1.87 | $2.00 | $1.8212 | $1.94 | 54.78K |
| Sep 18, 2026 | $1.82 | $2.10 | $1.81 | $1.91 | 199.5K |
| Sep 17, 2026 | $1.72 | $1.82 | $1.58 | $1.80 | 139.31K |
| Sep 16, 2026 | $1.86 | $2.279 | $1.70 | $1.78 | 796.98K |
| Sep 15, 2026 | $2.35 | $2.40 | $1.77 | $1.83 | 1.13M |
| Sep 14, 2026 | $2.45 | $2.67 | $2.38 | $2.59 | 109.61K |
| Sep 11, 2026 | $2.43 | $2.6561 | $2.35 | $2.43 | 78.1K |
| Sep 10, 2026 | $2.52 | $2.65 | $2.37 | $2.50 | 200.72K |
| Sep 9, 2026 | $2.87 | $2.87 | $2.42 | $2.47 | 171.28K |
| Sep 8, 2026 | $2.92 | $2.98 | $2.77 | $2.88 | 192.39K |
| Sep 4, 2026 | $2.55 | $2.87 | $2.55 | $2.72 | 167.04K |
| Sep 3, 2026 | $2.66 | $2.66 | $2.49 | $2.62 | 148.3K |
| Sep 2, 2026 | $2.88 | $2.895 | $2.56 | $2.67 | 203.34K |
| Sep 1, 2026 | $2.98 | $2.98 | $2.74 | $2.88 | 224.04K |
| Aug 31, 2026 | $3.10 | $3.55 | $2.84 | $3.00 | 1.23M |
The latest Smart Investors Daily articles mentioning PFSA.
PFSA research
Company profile and research snapshot.
Profusa Inc is a clinical-stage digital health and medical technology company focused on developing biosensing solutions to improve health outcomes for patients with a variety of different diseases and conditions. The Company's technology enables the development of bioengineered sensors that are designed to become one with the body to detect and continuously transmit actionable, clinical-grade data for personal and medical use. The Company's first offering in the European Union, the Lumee Oxygen Platform, is designed to report reliable tissue oxygen levels at various regions of interest, both acutely and long-term.
Visit company websiteConsensus and target data currently published for this company.
No generated briefing is available yet.
Yahoo · Sep 24, 2026
Profusa received a positive decision from GMED on ISO 13485 certification, expected in early October, while additional European MDR conformity assessment work remains before the Lumee Oxygen Platform can receive a CE mark. Key Investor TakeawaysProfusa (NASDAQ:PFSA) received a positive decision from notified body GMED regarding certification of its quality management system to ISO 13485.
Benzinga · Sep 24, 2026
Profusa received ISO 13485 certification from GMED, advancing its Lumee Oxygen Platform toward CE marking in the European Union.
Yahoo · Sep 15, 2026
Berkeley, CA, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (Nasdaq: PFSA) (the “Company”) announced today that on September 9, 2026, the Company received a letter (the “Compliance Determination Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”) confirming that the Company has demonstrated compliance with Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”) and Nasdaq Listing Rule 5550(b)(1) (the “Equity Rule”). The Company remains subject to a one-year Mandatory Panel Monitor (the “Monito
Benzinga · Sep 15, 2026
On September 9, 2026, the Company received a letter (the "Compliance Determination Letter") from The Nasdaq Stock Market LLC ("Nasdaq") confirming that the Company has demonstrated compliance with Nasdaq
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning PFSA.
